Among patients who underwent surgery, the 1-year recurrence-free survival rate was 75%.76 A similar observational study assessed the neoadjuvant use of anti-PD1 + TKI in 63 patients with unresectable HCC, where 15.9% of patients had successful downstaging and received curative resection at a median of 3.2 months after initiation of systemic therapy. Here, PDCD1 is linked to hepatocellular carcinoma.